XXXX using RNA interference-directed knockdown of @entity3820 .

@entity675 @entity263 @entity5 @entity19 @entity3820 @entity5049
OBJECTIVES: To determine whether @entity3820 ( @entity3820 ) plays a role in the tumorigenicity of @entity263 cells. METHODS: @entity5049 @entity263 cells were transfected with small interfering (si) @entity675 and siPDGFR-b, constructed according to the conventional small interfering RNA design standard. Reverse transcriptase polymerase chain reaction, Western blot analysis, and cell growth were studied to determine the characteristics of @entity675 and @entity3820 -b in vitro. The @entity263 xenograft model was established to investigate whether knockout of @entity675 and @entity3820 -b @entity263 @entity5 growth in vivo. The experimental groups were defined as group 1 ( @entity5049 cells only), group 2 ( @entity5049 cells transfected with small interfering green fluorescent protein), group 3 ( @entity5049 cells transfected with siPDGFR-a), group 4 ( @entity5049 cells transfected with siPDGFR-b), and group 5 ( @entity5049 cells transfected with siPDGFR-a and siPDGFR-b). RESULTS: Western blot analysis revealed that siPDGFR-a and siPDGFR-b significantly blocked @entity675 and @entity3820 -b protein expression. After 48 hours of transfection of the @entity5049 cells with siPDGFR-a and siPDGFR-b, the relative fractions of viable cells were reduced to 47.7% (P = .007) and 38.5% (P = .010). In vivo, @entity19 treated with siPDGFR-a or siPDGFR-b and siPDGFR-a plus siPDGFR-b had significant @entity5 cell growth arrest compared with the @entity19 in groups 1 and 2 (P = .001). In addition, a significant reduction in the microvessel density was observed in @entity5 from the @entity19 treated with siPDGFR-a or siPDGFR-b and siPDGFR-a plus siPDGFR-b (P < .001). CONCLUSIONS: The results of the present study suggest that siPDGFR-a and siPDGFR-b might inhibit @entity263 cell growth by the suppression of angiogenesis.
